These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 15270027)

  • 1. Hot drugs 2004.
    Nat Rev Drug Discov; 2004 Jul; Suppl():S3-40. PubMed ID: 15270027
    [No Abstract]   [Full Text] [Related]  

  • 2. Issues in bringing new drugs to the market.
    Tracey WR
    Science; 2005 Dec; 310(5753):1425-6; author reply 1425-6. PubMed ID: 16329172
    [No Abstract]   [Full Text] [Related]  

  • 3. New drugs of 1996.
    Hussar DA
    J Am Pharm Assoc (Wash); 1997; NS37(2):192-228; quiz 228-32. PubMed ID: 9069693
    [No Abstract]   [Full Text] [Related]  

  • 4. Prescription for trouble: common drugs, hidden dangers. Tens of people are at risk.
    Consum Rep; 2006 Jan; 71(1):34-9. PubMed ID: 16491527
    [No Abstract]   [Full Text] [Related]  

  • 5. Pharma's year of trouble and strife.
    Frantz S
    Nat Rev Drug Discov; 2006 Jan; 5(1):7-9. PubMed ID: 16485339
    [No Abstract]   [Full Text] [Related]  

  • 6. US court rules to allow experimental drugs for dying patients.
    Waltz E
    Nat Med; 2006 Jun; 12(6):596. PubMed ID: 16760988
    [No Abstract]   [Full Text] [Related]  

  • 7. A timely re-examination of drug polymorphism in pharmaceutical development and regulation.
    Grant DJ; Byrn SR
    Adv Drug Deliv Rev; 2004 Feb; 56(3):237-9. PubMed ID: 14962580
    [No Abstract]   [Full Text] [Related]  

  • 8. The FDA takes action against unapproved drugs.
    Meadows M
    FDA Consum; 2007; 41(1):34-5. PubMed ID: 17342837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Turning a blind eye.
    Nat Med; 2008 Jan; 14(1):1. PubMed ID: 18180702
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA proposes changes in access and charges for experimental drugs.
    Roehr B
    BMJ; 2007 Jan; 334(7583):12. PubMed ID: 17204787
    [No Abstract]   [Full Text] [Related]  

  • 11. Keeping up with drug safety information.
    Meadows M
    FDA Consum; 2006; 40(3):38-9. PubMed ID: 16906667
    [No Abstract]   [Full Text] [Related]  

  • 12. Strong medicine.
    Wadman M
    Nat Med; 2005 May; 11(5):465-6. PubMed ID: 15875044
    [No Abstract]   [Full Text] [Related]  

  • 13. Pharmaceutical postmarket review: fact or fiction?
    Schanz SJ
    Food Drug Law J; 2007; 62(3):493-500. PubMed ID: 17915391
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination products regulation at the FDA.
    Lauritsen KJ; Nguyen T
    Clin Pharmacol Ther; 2009 May; 85(5):468-70. PubMed ID: 19381151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 16. A stepwise approach to evaluating new drug therapy.
    Wessell A; Blair M
    JAAPA; 2001 Nov; 14(11):10-1. PubMed ID: 11766421
    [No Abstract]   [Full Text] [Related]  

  • 17. Science meets beauty: using medicine to improve appearances.
    Rados C
    FDA Consum; 2004; 38(2):30-5. PubMed ID: 15101363
    [No Abstract]   [Full Text] [Related]  

  • 18. The Food and Drug Administration's drug approval process.
    Ahart GJ
    Conn Med; 1980 Mar; 44(3):161-6. PubMed ID: 7363619
    [No Abstract]   [Full Text] [Related]  

  • 19. Dying to live.
    Nat Med; 2006 Jun; 12(6):593. PubMed ID: 16760985
    [No Abstract]   [Full Text] [Related]  

  • 20. Pharmacogenomics: an in-house advantage?
    Borchardt PE
    Drug Discov Today; 2006 Jan; 11(1-2):1-3. PubMed ID: 16478684
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.